{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:13:23Z","timestamp":1769044403828,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.072","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T23:59:19Z","timestamp":1712447959000},"page":"3066-3074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na\u00efve adults"],"prefix":"10.1016","volume":"42","author":[{"given":"J.F.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Polhemus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.E.","family":"Kester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.F.","family":"Ockenhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"R.A.","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Wortmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.K.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Schaecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Krzych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Tornieporth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Soisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Angov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.G.","family":"Heppner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2024.03.072_b0005","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.072_b0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Scp","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.072_b0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12936-022-04144-3","article-title":"Assessing the safety, impact and effectiveness of RTS, S\/AS01(E) malaria vaccine following its introduction in three sub-saharan african countries: methodological approaches and study set-up","volume":"21","author":"Praet","year":"2022","journal-title":"Malar J"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.072_b0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falciparum malaria. RTS, S malaria vaccine evaluation group","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.072_b0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S\/AS01B and RTS, S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2024.03.072_b0030","doi-asserted-by":"crossref","first-page":"e0131571","DOI":"10.1371\/journal.pone.0131571","article-title":"Ad35.CS.01-RTS, S\/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naive adults","volume":"10","author":"Ockenhouse","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.vaccine.2024.03.072_b0035","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.vaccine.2005.12.041","article-title":"A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS, S\/AS02A and MVA-CS","volume":"24","author":"Dunachie","year":"2006","journal-title":"Vaccine"},{"issue":"49","key":"10.1016\/j.vaccine.2024.03.072_b0040","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1016\/j.vaccine.2014.06.033","article-title":"Sequential phase 1 and phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS, S and TRAP formulated with AS02 adjuvant system in healthy, malaria naive adults","volume":"32","author":"Kester","year":"2014","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2024.03.072_b0045","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1016\/j.vaccine.2009.08.046","article-title":"Recombinant liver stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-GAMMA\/IL-2 CD4+ T cells but does not protect against experimental plasmodium falciparum infection","volume":"28","author":"Cummings","year":"2010","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2024.03.072_b0050","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1016\/j.vaccine.2005.11.028","article-title":"Phase I safety and immunogenicity trial of FMP1\/AS02A, a plasmodium falciparum MSP-1 asexual blood stage vaccine","volume":"24","author":"Ockenhouse","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.072_b0055","doi-asserted-by":"crossref","first-page":"e5254","DOI":"10.1371\/journal.pone.0005254","article-title":"Phase 1\/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A","volume":"4","author":"Spring","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.072_b0060","unstructured":"Cummings J, Polhemus ME, Kester ME, Ockenhouse CF, Gasser RA Jr, Magill Aj, et al.. Safety, immunogenicity and efficacy of candidate malaria vaccines containing CSP and MSP-1 antigens. ASTMH; 10-14 November 2002; Denver2002."},{"key":"10.1016\/j.vaccine.2024.03.072_b0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1475-2875-8-183","article-title":"MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of plasmodium falciparum","volume":"8","author":"Bergmann-Leitner","year":"2009","journal-title":"Malar J"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.072_b0070","doi-asserted-by":"crossref","first-page":"e4708","DOI":"10.1371\/journal.pone.0004708","article-title":"Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya","volume":"4","author":"Ogutu","year":"2009","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.072_b0075","doi-asserted-by":"crossref","first-page":"e79323","DOI":"10.1371\/journal.pone.0079323","article-title":"Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial","volume":"8","author":"Laurens","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.072_b0080","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","article-title":"A field trial to assess a blood-stage malaria vaccine","volume":"365","author":"Thera","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.072_b0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0166-6851(03)00077-X","article-title":"Development and pre-clinical analysis of a plasmodium falciparum merozoite surface Protein-1(42) malaria vaccine","volume":"128","author":"Angov","year":"2003","journal-title":"Mol Biochem Parasitol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.072_b0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/14760584.2.2.231","article-title":"Development of RTS, S\/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant","volume":"2","author":"Garcon","year":"2003","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.072_b0095","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1086\/318534","article-title":"Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental plasmodium falciparum malaria","volume":"183","author":"Kester","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.072_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fdata.2021.672460","article-title":"Comprehensive data integration approach to assess immune responses and correlates of RTS, S\/AS01-mediated protection from malaria infection in controlled human malaria infection trials","volume":"4","author":"Young","year":"2021","journal-title":"Front Big Data"},{"issue":"7","key":"10.1016\/j.vaccine.2024.03.072_b0105","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1371\/journal.pctr.0010034","article-title":"Safety and allele-specific immunogenicity of a malaria vaccine in malian adults: results of a phase I randomized trial","volume":"1","author":"Thera","year":"2006","journal-title":"PLoS Clin Trials"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.072_b0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.vaccine.2005.11.037","article-title":"Phase 1 randomized double-blind safety and immunogenicity trial of plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya","volume":"25","author":"Stoute","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2024.03.072_b0115","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1371\/journal.pctr.0010032","article-title":"Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children","volume":"1","author":"Withers","year":"2006","journal-title":"PLoS Clin Trials"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.072_b0120","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/infdis\/jiw039","article-title":"Demonstration of the blood-stage plasmodium falciparum controlled human malaria infection model to assess efficacy of the P. falciparum apical membrane antigen 1 vaccine, FMP2.1\/AS01","volume":"213","author":"Payne","year":"2016","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.072_b0125","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.medj.2021.03.014","article-title":"Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination","volume":"2","author":"Minassian","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.vaccine.2024.03.072_b0130","unstructured":"Malaria Vaccine: WHO position paper - March 2022. World Health Organization; 2022."},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.072_b0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1473-3099(23)00368-7","article-title":"Seasonal vaccination with RTS, S\/AS01(E) vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial","volume":"24","author":"Dicko","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.072_b0140","article-title":"Implementation strategies for the introduction of the RTS, S\/AS01 (RTS, S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report","volume":"22(1):242","author":"Merle","year":"2023","journal-title":"Malar J"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.072_b0145","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40259-023-00623-4","article-title":"Malaria vaccines: progress to date","volume":"37","author":"Stanisic","year":"2023","journal-title":"BioDrugs"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.072_b0150","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1080\/21645515.2021.1947762","article-title":"Novel malaria vaccines","volume":"17","author":"Laurens","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.vaccine.2024.03.072_b0155","article-title":"Malaria vaccines: from the past towards the mRNA vaccine era","volume":"11","author":"Tsoumani","year":"2023","journal-title":"Vaccines (Basel)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400389X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400389X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:54:52Z","timestamp":1725688492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2400389X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X2400389X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na\u00efve adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}